在高级和多个BCC上使用Vismodegib的现实世界经验:来自RELIVIS研究的数据
Verónica Ruiz-Salas1, Sebastian Podlipnik2,3, Alejandra Sandoval-Clavijo2,3
1Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
在现实环境中,Vismodegib有效地治疗先进的基底细胞癌. 完全反应后的复发风险低于报告的水平,对许多患者来说,用vismodegib重新治疗是可行的选择.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
背景情况:
- 维斯莫迪吉布已被批准用于高级基底细胞癌 (BCC) 病例,不适合进行手术或放射治疗.
- 关于vismodegib实际临床应用的有限的大规模研究存在.
研究的目的:
- 分析接受vismodegib治疗高级BCC的患者在多中心,现实世界的环境中的结果,包括复发和治疗耐药性.
- 为了评估治疗失败和复发的治疗管理在高级BCC患者在vismodegib.
主要方法:
- 一项涉及15个专业中心的全国性回顾性研究.
- 收集关于患者/瘤特征,vismodegib疗效,安全性,复发率和随后治疗的数据.
- 多变量逻辑回归确定了完整临床反应的预测因素.
主要成果:
- 133名晚期BCC患者的客观应答率 (ORR) 为77.5%,其中45.9%实现完全缓解.
- 在具有长期数据的115名患者中,只有34%的患者接受了进一步的治疗或vismodegib重新挑战.
- 69%的初始完全响应的患者没有复发;30.7%的患者复发. 在Rechallenge的结果中,ORR达到55.5%.
结论:
- 在常规临床实践中,Vismodegib在晚期的基底细胞癌中显示出有效性.
- 完整反应后的复发风险似乎低于之前报告的水平.
- 对显著比例的患者来说,Vismodegib重试是可行的和有效的.
更多相关视频
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
相关概念视频
Treatment Resistant Cancers
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Clinical Applications of Epidermal Stem Cells
Clinical Trials
There are four phases in a clinical trial. A phase one...
